Table 3 Composition of each latent class
| Â | ERAN | BSRBR TNF inhibitor cohort | BSRBR non-biologic cohort | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Concordant/discordant | Con | Con | Con | Dis | Dis | Con | Con | Dis | Dis | Con | Con | Dis | Dis |
Descriptor | Mild | Moderate | Severe | Better patient-reported | Worse patient-reported | Moderate | Severe | Better patient-reported | Worse patient-reported | Mild | Moderate | Better patient-reported | Worse patient-reported |
Number of subjects | 220 | 329 | 86 | 91 | 102 | 1544 | 2117 | 2289 | 3955 | 476 | 1308 | 248 | 549 |
Percentage of total | 26% | 38% | 10% | 11% | 12% | 16% | 21% | 23% | 40% | 18% | 51% | 10% | 21% |
ESR | 22 (19) | 25 (18) | 42 (29) | 40 (26) | 44 (29) | 42 (27) | 52 (31) | 39 (26) | 49 (29) | 27 (21) | 33 (23) | 44 (28) | 38 (26) |
SJC | 3 (3) | 4 (3) | 12 (6) | 14 (5) | 7 (4) | 9 (5) | 15 (6) | 14 (6) | 9 (5) | 4 (4) | 5 (3) | 16 (5) | 6 (4) |
TJC | 2 (3) | 5 (4) | 22 (4) | 11 (5) | 9 (5) | 9 (4) | 23 (4) | 21 (4) | 11 (4) | 4 (4) | 7 (5) | 20 (6) | 11 (6) |
VAS | 20 (15) | 44 (20) | 66 (20) | 50 (20) | 73 (16) | 57 (20) | 84 (15) | 69 (19) | 74 (18) | 34 (21) | 51 (21) | 72 (18) | 69 (16) |
BP | 46 (6) | 31 (7) | 24 (6) | 32 (6) | 22 (5) | 34 (7) | 20 (4) | 27 (6) | 23 (5) | 43 (6) | 31 (5) | 27 (7) | 23 (5) |
VT | 52 (9) | 40 (8) | 33 (8) | 46 (8) | 30 (8) | 45 (9) | 25 (6) | 39 (9) | 30 (7) | 51 (7) | 39 (7) | 36 (9) | 28 (6) |
MH | 55 (7) | 45 (9) | 39 (9) | 52 (8) | 32 (10) | 50 (9) | 32 (10) | 46 (9) | 38 (10) | 56 (7) | 47 (9) | 43 (10) | 32 (9) |
Probability of membership of latent class | |||||||||||||
  > 80% probability | 89% | 73% | 78% | 57% | 70% | 66% | 65% | 53% | 66% | 74% | 74% | 77% | 63% |
  > 95% probability | 71% | 40% | 56% | 30% | 41% | 40% | 37% | 22% | 38% | 51% | 36% | 59% | 38% |